FCIT has had a solid few weeks, with the shares up 6.7% over the past month to 349.8p — yet the lending market tells a story of almost complete indifference from short sellers.
The positioning picture here is about as benign as it gets. Borrow availability is effectively uncapped, running at multiples of outstanding short interest with around 43 million shares available to lend. The ORTEX short score has drifted lower all week, easing to 25.3 from 25.9 ten days ago — a low reading that reflects minimal short-side conviction. Cost to borrow has also eased sharply, falling 32% on the week to just 0.66%. That's not a lending market under any stress; it's one where borrowers face almost no friction, and yet very few are bothering to show up. Taken together, these signals point to a stock that the short-selling community is largely ignoring.
The ownership picture reinforces that read. Columbia Management holds a dominant 41% stake, locking up a large portion of the register in what appears to be a long-term strategic position — likely reflecting FCIT's role as the underlying vehicle for Columbia Threadneedle's managed fund clients. Aberdeen adds another 8.7%, and a cluster of UK wealth managers including Hargreaves Lansdown (7.6%) and Rathbones (2.8%) round out the top holders. Flows at the margin have been mixed: Hargreaves trimmed by around 2.2 million shares in the latest reported period, while Schroder added nearly 1.9 million and BlackRock picked up just over 1 million. Nothing in the institutional flow data looks alarming — this is routine rebalancing, not a directional bet.
What is genuinely noteworthy is the trust's fundamental backdrop, documented in a recent update. FCIT delivered a NAV total return of +12.3% over the prior year, beating its FTSE All-World benchmark by 1.8 percentage points. The board raised the dividend for the 55th consecutive year, cementing its AIC Dividend Hero status. With the shares recently trading at a 4.2% discount to NAV, the trust offers global equity exposure at a modest haircut to net asset value — a combination that historically draws steady retail and wealth-manager demand without generating short-side interest. Analyst coverage is essentially absent from the live data, and valuation multiples are too stale to draw on with confidence.
Insider activity has been quiet. The most recent disclosed purchase — a small buy by Independent Director Steve Russell in January — registered a significance score of just 3 out of 10. A steady trickle of small director purchases has been the pattern going back through 2024, none material enough to move the needle. Earnings event data shows the shares have responded modestly to results releases, with 1-day moves clustering in the 0.6%–1.7% range on the upside in recent quarters, though the 2025 August release saw a marginal dip. No next earnings date is scheduled in the data.
The main thing to watch is whether the discount to NAV narrows further as global equity markets continue to recover — and whether the steady wealth-manager trimming in names like Hargreaves and Rathbones picks up pace or reverses as the UK advisory community reassesses large-cap investment trust allocations into the second half of the year.
See the live data behind this article on ORTEX.
Open FCIT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
